Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2018 5,50 M
EBIT 2018 -32,6 M
Net income 2018 -33,2 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 -
Capi. / Sales2018 4,95x
Capi. / Sales2019 -
Capitalization 27,2 M
More Financials
Company
Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections.Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital... 
More about the company
Latest news on BIOTA PHARMACEUTICALS INC
09/28 AVIRAGEN THERAPEUTICS, INC. (NASDAQ : AVIR) Files An 8-K Notice of Delisting or ..
09/27 AVIRAGEN THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Contin..
09/25 AVIRAGEN THERAPEUTICS INC : Earnings Review and Free Research Report: Aviragen R..
09/21 AVIRAGEN THERAPEUTICS (NASDAQ : AVIR) Files An 8-K Notice of Delisting or Failur..
09/20 AVIRAGEN THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Contin..
09/05 AVIRAGEN THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fin..
09/01 AVIRAGEN THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
08/31 Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial R..
08/16 AVIRAGEN THERAPEUTICS : Biotech Stock Performance Review -- Aralez Pharma, Arena..
07/04 BANCO LATINOAMERICANO DE COMERCI EXT : BLX) Analysts See $0.69 EPS, Shorts at Av..
More news
Sector news : Bio Therapeutic Drugs
06:58p Regeneron-Sanofi drug succeeds mid-stage study
06:39pDJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
06:48aDJJOHNSON & JOHNSON : Raises Guidance on Earnings Beat
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
More sector news : Bio Therapeutic Drugs
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 3
Average target price 5,00 $
Spread / Average Target 609%
EPS Revisions
Managers
NameTitle
Joseph M. Patti President, CEO & Executive Director
Russell H. Plumb Executive Chairman
Mark P. Colonnese Chief Financial Officer & Executive Vice President
Anna Novotney-Barry Vice President-Clinical Development
John H. Vernachio Vice President-Preclinical Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOTA PHARMACEUTICALS INC27
GILEAD SCIENCES11.65%104 409
REGENERON PHARMACEUTICALS20.67%47 756
VERTEX PHARMACEUTICALS107.56%39 003
ACTELION23.24%29 757
GENMAB22.08%13 881